Mak R H
Department of Pediatrics, Stanford University School of Medicine, California, USA.
J Pediatr. 1996 Jul;129(1):97-104. doi: 10.1016/s0022-3476(96)70195-6.
To determine whether anemia is important in the pathogenesis of metabolic abnormalities in insulin, amino acid, and lipid metabolism in uremia.
Twelve adolescents (15 +/- 1 years of age) undergoing long-term dialysis were studied before and after correction of their anemia by human recombinant erythropoietin at a mean interval of 6 months. Six patients received hemodialysis, and six received continuous-cycling peritoneal dialysis. Insulin sensitivity was measured by the euglycemic clamp technique and insulin secretion by the hyperglycemic clamp technique in these patients.
Hematocrit increased from 0.219 +/- 0.006 to 0.344 +/- 0.007 (p <0.01). Ferritin concentration did not change significantly (11,252 +/- 356 mg/dl to 785 +/- 226 mg/dl). Serum iron concentration decreased from 134 +/- 13 mg/dl to 83 +/- 11 mg/dl, and percentage saturation decreased from 56 +/- 4 to 41 +/- 5 (p <0.05 in both cases). There were no significant changes in weight, height, blood pressure, caloric intake, triceps skinfold thickness, or arm muscular area. There were also no significant changes in serum calcium, phosphate, bicarbonate, albumin, creatinine, or blood urea nitrogen concentration. Insulin sensitivity increased by 33% (p <0.01), but insulin secretion did not change significantly. Insulin sensitivity during the euglycemic clamp studies in patients before erythropoietin therapy was lower (145 +/- 10 mg/m2 per minute; p <0.01) than published normal values (201 +/- 12 mg/m2 per minute) and was normal after erythropoietin therapy (193 +/- 11 mg/m2 per minute). Insulin secretion was low in patients before erythropoietin therapy (44 +/- 8 microU/ml) compared with published normal values (68 +/- 6 microU/ml) and did not change after erythropoietin therapy (46 +/- 4 microU/ml). Plasma concentrations of branched-chain amino acids and lipids in the patients were compared with values from eight healthy adolescents. Plasma concentrations of valine, leucine, and isoleucine were low before treatment and were normal after 6 months of erythropoietin therapy. Plasma concentrations of triglycerides, total cholesterol, and low-density lipoprotein cholesterol were all high before treatment and were normal after treatment of anemia.
Treatment of anemia by erythropoietin reversed insulin resistance as well as amino acid and lipid abnormalities in adolescents undergoing dialysis.
确定贫血在尿毒症患者胰岛素、氨基酸及脂质代谢异常的发病机制中是否起重要作用。
对12名接受长期透析的青少年(平均年龄15±1岁)进行研究,在使用重组人促红细胞生成素纠正贫血前后,平均间隔6个月。6例患者接受血液透析,6例接受持续循环腹膜透析。通过正常血糖钳夹技术测定这些患者的胰岛素敏感性,通过高血糖钳夹技术测定胰岛素分泌。
血细胞比容从0.219±0.006增至0.344±0.007(p<0.01)。铁蛋白浓度无显著变化(从11,252±356mg/dl降至785±226mg/dl)。血清铁浓度从134±13mg/dl降至83±11mg/dl,饱和度百分比从56±4降至41±5(两者p均<0.05)。体重、身高、血压、热量摄入、肱三头肌皮褶厚度或上臂肌肉面积均无显著变化。血清钙、磷、碳酸氢盐、白蛋白、肌酐或血尿素氮浓度也无显著变化。胰岛素敏感性增加了33%(p<0.01),但胰岛素分泌无显著变化。促红细胞生成素治疗前患者在正常血糖钳夹研究期间的胰岛素敏感性较低(145±10mg/m²每分钟;p<0.01),低于已发表的正常值(201±12mg/m²每分钟),促红细胞生成素治疗后恢复正常(193±11mg/m²每分钟)。促红细胞生成素治疗前患者的胰岛素分泌较低(44±8微单位/毫升),低于已发表的正常值(68±6微单位/毫升),促红细胞生成素治疗后无变化(46±4微单位/毫升)。将患者的血浆支链氨基酸和脂质浓度与8名健康青少年的值进行比较。治疗前缬氨酸、亮氨酸和异亮氨酸的血浆浓度较低,促红细胞生成素治疗6个月后恢复正常。治疗前甘油三酯、总胆固醇和低密度脂蛋白胆固醇的血浆浓度均较高,贫血治疗后恢复正常。
促红细胞生成素治疗贫血可逆转接受透析青少年的胰岛素抵抗以及氨基酸和脂质异常。